TheStreet's Jim Cramer notes Cubist's major drug could come off patent in 2018. But he has had the company on his show Mad Money on CNBC a few times, and Cubist has claimed it has some blockbuster products in the pipe with regard to "superbugs."
Cramer points out that these "superbugs" land people in the hospital and the sicknesses are essentially fatal. He says that any company that has a formulation that can wipe out the diseases that occur in hospitals could have a larger market than people realize, and this is why he thinks Merck is buying Cubist.
Cramer says he is in favor of this acquisition if Cubist really has something. If not, then this would be a huge write off, Cramer adds. But he says he does not believe that Merck and CEO Ken Frazier would "do something that irresponsible" without believing that Cubist has "superbug" cures in its pipe.CBST data by YCharts